{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T10:09:59Z","timestamp":1793527799192,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["2024-05846"],"award-info":[{"award-number":["2024-05846"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000082","name":"Cystic Fibrosis Canada","doi-asserted-by":"publisher","award":["CFC 1019378"],"award-info":[{"award-number":["CFC 1019378"]}],"id":[{"id":"10.13039\/501100000082","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Government of Alberta - Major Innovation Fund","award":["RCP-19-003-MIF"],"award-info":[{"award-number":["RCP-19-003-MIF"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-30556-7","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T03:07:09Z","timestamp":1764904029000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Synergy between ciprofloxacin and temperate phages overcomes therapeutic limitations caused by lysogen formation"],"prefix":"10.1038","volume":"16","author":[{"given":"P.","family":"Lauman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. R. H.","family":"Cassell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.","family":"Dennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"30556_CR1","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","volume":"404","author":"M Naghavi","year":"2024","unstructured":"Naghavi, M. et al. Global burden of bacterial antimicrobial resistance 1990\u20132021: A systematic analysis with forecasts to 2050. Lancet 404, 1199\u20131226 (2024).","journal-title":"Lancet"},{"key":"30556_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa464","volume-title":"Buying Time: The AMR Action Fund and the State of Antibiotic Development in the United States 2020","author":"CJ Clancy","year":"2020","unstructured":"Clancy, C. J. & Hong, N. M. Buying Time: The AMR Action Fund and the State of Antibiotic Development in the United States 2020 (Oxford University Press, 2020). https:\/\/doi.org\/10.1093\/ofid\/ofaa464."},{"key":"30556_CR3","unstructured":"O\u2019Neill J. Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations. The Review on Antimicrobial Resistance. London, UK. 2014."},{"key":"30556_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.resmic.2007.07.005","author":"F d\u2019Herelle","year":"1917","unstructured":"d\u2019Herelle, F. On an invisible microbe antagonistic toward dysenteric bacilli. CR Acad. Sci. https:\/\/doi.org\/10.1016\/j.resmic.2007.07.005 (1917).","journal-title":"CR Acad. Sci."},{"key":"30556_CR5","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4161\/bact.1.2.15845","volume":"1","author":"ST Abedon","year":"2011","unstructured":"Abedon, S. T., Kuhl, S. J., Blasdel, B. G. & Kutter, E. M. Phage treatment of human infections. Bacteriophage 1, 66\u201385 (2011).","journal-title":"Bacteriophage"},{"key":"30556_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.00954-17","volume":"61","author":"RT Schooley","year":"2017","unstructured":"Schooley, R. T. et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob. Agents Chemother. 61, 10\u20131128 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"30556_CR7","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/s41564-024-01705-x","volume":"9","author":"JP Pirnay","year":"2024","unstructured":"Pirnay, J. P. et al. Personalized bacteriophage therapy outcomes for 100 consecutive cases: A multicentre, multinational, retrospective observational study. Nat. Microbiol. 9, 1434\u20131453 (2024).","journal-title":"Nat. Microbiol."},{"key":"30556_CR8","doi-asserted-by":"publisher","first-page":"e799","DOI":"10.1371\/journal.pone.0000799","volume":"2","author":"AM Comeau","year":"2007","unstructured":"Comeau, A. M., T\u00e9tart, F., Trojet, S. N., Pr\u00e8re, M. F. & Krisch, H. M. Phage-antibiotic synergy (PAS): \u03b2-lactam and quinolone antibiotics stimulate virulent phage growth. PLoS ONE 2, e799 (2007).","journal-title":"PLoS ONE"},{"key":"30556_CR9","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1128\/AEM.02850-14","volume":"81","author":"F Kamal","year":"2015","unstructured":"Kamal, F. & Dennis, J. J. Burkholderia cepacia complex phage-antibiotic synergy (PAS): Antibiotics stimulate lytic phage activity. Appl. Environ. Microbiol. 81, 1132\u20131138 (2015).","journal-title":"Appl. Environ. Microbiol."},{"key":"30556_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2015.12.011","author":"C Torres-Barcel\u00f3","year":"2016","unstructured":"Torres-Barcel\u00f3, C. & Hochberg, M. E. Evolutionary rationale for phages as complements of antibiotics. Trends Microbiol. https:\/\/doi.org\/10.1016\/j.tim.2015.12.011 (2016).","journal-title":"Trends Microbiol."},{"key":"30556_CR11","doi-asserted-by":"publisher","first-page":"26717","DOI":"10.1038\/srep26717","volume":"6","author":"BK Chan","year":"2016","unstructured":"Chan, B. K. et al. Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci. Rep. 6, 26717 (2016).","journal-title":"Sci. Rep."},{"key":"30556_CR12","doi-asserted-by":"publisher","first-page":"e02085","DOI":"10.1128\/AEM.02085-18","volume":"84","author":"M Kim","year":"2018","unstructured":"Kim, M. et al. Phage-antibiotic synergy via delayed lysis. Appl. Environ. Microbiol. 84, e02085-e2118 (2018).","journal-title":"Appl. Environ. Microbiol."},{"key":"30556_CR13","doi-asserted-by":"publisher","first-page":"109172","DOI":"10.1016\/j.celrep.2021.109172","volume":"35","author":"AM Al-Anany","year":"2021","unstructured":"Al-Anany, A. M., Fatima, R. & Hynes, A. P. Temperate phage-antibiotic synergy eradicates bacteria through depletion of lysogens. Cell Rep. 35, 109172 (2021).","journal-title":"Cell Rep."},{"key":"30556_CR14","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3390\/antibiotics14060545","volume":"14","author":"BSI Supina","year":"2025","unstructured":"Supina, B. S. I. & Dennis, J. J. The current landscape of phage-antibiotic synergistic (PAS) interactions. Antibiotics 14, 545 (2025).","journal-title":"Antibiotics"},{"key":"30556_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3564","volume-title":"A century of the phage: Past, present and future","author":"GPC Salmond","year":"2015","unstructured":"Salmond, G. P. C. & Fineran, P. C. A century of the phage: Past, present and future (Nature Publishing Group, 2015). https:\/\/doi.org\/10.1038\/nrmicro3564."},{"key":"30556_CR16","doi-asserted-by":"publisher","unstructured":"Hobbs Z, Abedon ST. Diversity of phage infection types and associated terminology: the problem with \u2018Lytic or lysogenic.\u2019 FEMS Microbiol Lett. Oxford University Press https:\/\/doi.org\/10.1093\/FEMSLE\/FNW047 2016.","DOI":"10.1093\/FEMSLE\/FNW047"},{"key":"30556_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/ismej.2017.16","volume-title":"Lysogeny in nature: Mechanisms, impact and ecology of temperate phages","author":"C Howard-Varona","year":"2017","unstructured":"Howard-Varona, C., Hargreaves, K. R., Abedon, S. T. & Sullivan, M. B. Lysogeny in nature: Mechanisms, impact and ecology of temperate phages (Nature Publishing Group, 2017). https:\/\/doi.org\/10.1038\/ismej.2017.16."},{"key":"30556_CR18","doi-asserted-by":"publisher","first-page":"e04430","DOI":"10.1128\/spectrum.04430-22","volume":"11","author":"P Lauman","year":"2023","unstructured":"Lauman, P. & Dennis, J. J. Synergistic interactions among burkholderia cepacia complex-targeting phages reveal a novel therapeutic role for lysogenization-capable phages. Microbiol. Spectr. 11, e04430-e4522 (2023).","journal-title":"Microbiol. Spectr."},{"key":"30556_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s44259-025-00117-z","volume":"3","author":"BWM Cook","year":"2025","unstructured":"Cook, B. W. M. & Hynes, A. P. Re-evaluating what makes a phage unsuitable for therapy. npj Antimicrobials Resistance 3, 45 (2025).","journal-title":"npj Antimicrobials Resistance"},{"key":"30556_CR20","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.genet.39.073003.113656","author":"AB Oppenheim","year":"2005","unstructured":"Oppenheim, A. B., Kobiler, O., Stavans, J., Court, D. L. & Adhya, S. Switches in bacteriophage lambda development. Annu. Rev. Genet. https:\/\/doi.org\/10.1146\/annurev.genet.39.073003.113656 (2005).","journal-title":"Annu. Rev. Genet."},{"key":"30556_CR21","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.virol.2006.03.001","volume":"350","author":"X Sun","year":"2006","unstructured":"Sun, X., G\u00f6hler, A., Heller, K. J. & Neve, H. The ltp gene of temperate Streptococcus thermophilus phage TP-J34 confers superinfection exclusion to Streptococcus thermophilus and Lactococcus lactis. Virology 350, 146\u2013157 (2006).","journal-title":"Virology"},{"key":"30556_CR22","doi-asserted-by":"publisher","first-page":"354","DOI":"10.4161\/viru.24498","volume":"4","author":"LC Fortier","year":"2013","unstructured":"Fortier, L. C. & Sekulovic, O. Importance of prophages to evolution and virulence of bacterial pathogens. Virulence 4, 354\u2013365 (2013).","journal-title":"Virulence"},{"key":"30556_CR23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/mBio.00971-19","volume":"10","author":"TN Mavrich","year":"2019","unstructured":"Mavrich, T. N. & Hatfull, G. F. Evolution of superinfection immunity in cluster A mycobacteriophages. MBio 10, 10\u20131128 (2019).","journal-title":"MBio"},{"key":"30556_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmm.2005.09.002","author":"M Skurnik","year":"2006","unstructured":"Skurnik, M. & Strauch, E. Phage therapy: Facts and fiction. Int. J. Med. Microbiol. https:\/\/doi.org\/10.1016\/j.ijmm.2005.09.002 (2006).","journal-title":"Int. J. Med. Microbiol."},{"key":"30556_CR25","doi-asserted-by":"publisher","first-page":"12127","DOI":"10.1073\/pnas.1405336111","volume":"111","author":"LM Bobay","year":"2014","unstructured":"Bobay, L. M., Touchon, M. & Rocha, E. P. C. Pervasive domestication of defective prophages by bacteria. Proc. Natl. Acad. Sci. U S A 111, 12127\u201312132 (2014).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"30556_CR26","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1038\/ismej.2016.47","volume":"10","author":"M Touchon","year":"2016","unstructured":"Touchon, M., Bernheim, A. & Rocha, E. P. C. Genetic and life-history traits associated with the distribution of prophages in bacteria. ISME J. 10, 2744\u20132754 (2016).","journal-title":"ISME J."},{"key":"30556_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2018.10.008","author":"R Monteiro","year":"2019","unstructured":"Monteiro, R., Pires, D. P., Costa, A. R. & Azeredo, J. Phage therapy: Going temperate?. Trends Microbiol. https:\/\/doi.org\/10.1016\/j.tim.2018.10.008 (2019).","journal-title":"Trends Microbiol."},{"key":"30556_CR28","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1128\/AEM.71.2.1079-1083.2005","volume":"71","author":"S Goh","year":"2005","unstructured":"Goh, S., Riley, T. V. & Chang, B. J. Isolation and characterization of temperate bacteriophages of Clostridium difficile. Appl. Environ. Microbiol. 71, 1079\u20131083 (2005).","journal-title":"Appl. Environ. Microbiol."},{"key":"30556_CR29","doi-asserted-by":"publisher","first-page":"556706","DOI":"10.3389\/fmicb.2020.556706","volume":"11","author":"A Ambroa","year":"2020","unstructured":"Ambroa, A. et al. Temperate bacteriophages (Prophages) in pseudomonas aeruginosa isolates belonging to the international cystic fibrosis clone (CC274). Front. Microbiol. 11, 556706 (2020).","journal-title":"Front. Microbiol."},{"key":"30556_CR30","doi-asserted-by":"publisher","first-page":"e02559","DOI":"10.1128\/mbio.02559-24","volume":"16","author":"R Fatima","year":"2025","unstructured":"Fatima, R. & Hynes, A. P. Temperate phage-antibiotic synergy is widespread\u2014extending to Pseudomonas\u2014but varies by phage, host strain, and antibiotic pairing. MBio 16, e02559-e2624 (2025).","journal-title":"MBio"},{"key":"30556_CR31","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1073\/pnas.1714658115","volume":"115","author":"S Kilcher","year":"2018","unstructured":"Kilcher, S. et al. Cross-genus rebooting of custom-made, synthetic bacteriophage genomes in L-form bacteria. Proc. Natl. Acad. Sci. U S A 115, 567\u2013572 (2018).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"30556_CR32","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","volume":"25","author":"RM Dedrick","year":"2019","unstructured":"Dedrick, R. M. et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat. Med. 25, 730\u2013733 (2019).","journal-title":"Nat. Med."},{"key":"30556_CR33","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1128\/JVI.01843-09","volume":"84","author":"KH Lynch","year":"2010","unstructured":"Lynch, K. H., Seed, K. D., Stothard, P. & Dennis, J. J. Inactivation of Burkholderia cepacia Complex Phage KS9 gp41 Identifies the Phage Repressor and Generates Lytic Virions. J. Virol. 84, 1276\u20131288 (2010).","journal-title":"J. Virol."},{"key":"30556_CR34","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3389\/fmicb.2014.00184","volume":"5","author":"KR Hargreaves","year":"2014","unstructured":"Hargreaves, K. R. & Clokie, M. R. J. Clostridium difficile phages: Still difficult?. Front. Microbiol. 5, 184 (2014).","journal-title":"Front. Microbiol."},{"key":"30556_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/v13071331","author":"P Lauman","year":"2021","unstructured":"Lauman, P. & Dennis, J. J. Advances in phage therapy: Targeting the Burkholderia cepacia complex. Viruses https:\/\/doi.org\/10.3390\/v13071331 (2021).","journal-title":"Viruses"},{"key":"30556_CR36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.anaerobe.2013.05.001","volume":"22","author":"E Meader","year":"2013","unstructured":"Meader, E., Mayer, M. J., Steverding, D., Carding, S. R. & Narbad, A. Evaluation of bacteriophage therapy to control Clostridium difficile and toxin production in an in vitro human colon model system. Anaerobe 22, 25\u201330 (2013).","journal-title":"Anaerobe"},{"key":"30556_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antibiotics7010013","volume":"7","author":"JY Nale","year":"2018","unstructured":"Nale, J. Y., Redgwell, T. A., Millard, A. & Clokie, M. R. J. Efficacy of an optimised bacteriophage cocktail to clear Clostridium difficile in a batch fermentation model. Antibiotics 7, 1\u201315 (2018).","journal-title":"Antibiotics"},{"key":"30556_CR38","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3389\/fmicb.2016.01383","volume":"7","author":"JY Nale","year":"2016","unstructured":"Nale, J. Y., Chutia, M., Carr, P., Hickenbotham, P. T. & Clokie, M. R. J. \u201cGet in early\u201d; Biofilm and wax moth (Galleria mellonella) models reveal new insights into the therapeutic potential of Clostridium difficile bacteriophages. Front. Microbiol. 7, 1383 (2016).","journal-title":"Front. Microbiol."},{"key":"30556_CR39","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1128\/AAC.01774-15","volume":"60","author":"JY Nale","year":"2016","unstructured":"Nale, J. Y. et al. Bacteriophage combinations significantly reduce Clostridium difficile growth in vitro and proliferation in vivo. Antimicrob. Agents Chemother. 60, 968\u2013981 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"30556_CR40","doi-asserted-by":"publisher","DOI":"10.1128\/aem.01317-24","author":"P Lauman","year":"2024","unstructured":"Lauman, P. & Dennis, J. J. Prophylactic phage biocontrol prevents Burkholderia gladioli infection in a quantitative ex planta model of bacterial virulence. Appl. Environ. Microbiol. https:\/\/doi.org\/10.1128\/aem.01317-24 (2024).","journal-title":"Appl. Environ. Microbiol."},{"key":"30556_CR41","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1128\/AAC.01166-08","volume":"53","author":"KD Seed","year":"2009","unstructured":"Seed, K. D. & Dennis, J. J. Experimental bacteriophage therapy increases survival of Galleria mellonella larvae infected with clinically relevant strains of the Burkholderia cepacia complex. Antimicrob. Agents Chemother. 53, 2205\u20132208 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"30556_CR42","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1086\/649227","volume":"201","author":"LA Carmody","year":"2010","unstructured":"Carmody, L. A. et al. Efficacy of bacteriophage therapy in a model of burkholderia cenocepacia pulmonary infection. J. Infect. Dis. 201, 264\u2013271 (2010).","journal-title":"J. Infect. Dis."},{"key":"30556_CR43","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1128\/AAC.02388-13","volume":"58","author":"DD Semler","year":"2014","unstructured":"Semler, D. D., Goudie, A. D., Finlay, W. H. & Dennis, J. J. Aerosol phage therapy efficacy in Burkholderia cepacia complex respiratory infections. Antimicrob. Agents Chemother. 58, 4005\u20134013 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"30556_CR44","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s00253-016-7924-7","volume":"101","author":"B Roszniowski","year":"2017","unstructured":"Roszniowski, B. et al. The temperate Burkholderia phage AP3 of the Peduovirinae shows efficient antimicrobial activity against B. cenocepacia of the IIIA lineage. Appl. Microbiol. Biotechnol. 101, 1203\u20131216 (2017).","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"30556_CR45","doi-asserted-by":"publisher","first-page":"5612","DOI":"10.1128\/AAC.00504-12","volume":"56","author":"IY Chung","year":"2012","unstructured":"Chung, I. Y., Sim, N. & Cho, Y. H. Antibacterial efficacy of temperate phage-mediated inhibition of bacterial group motilities. Antimicrob. Agents Chemother. 56, 5612\u20135617 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"30556_CR46","first-page":"1","volume":"267","author":"DM Demarini","year":"1992","unstructured":"Demarini, D. M. & Lawrence, B. K. Prophage induction by DNA topoisomerase II poisons and reactive-oxygen species: Role of DNA breaks. Mutat. Res. 267, 1\u201317 (1992).","journal-title":"Mutat. Res."},{"key":"30556_CR47","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1128\/AAC.50.1.171-177.2006","volume":"50","author":"C Goerke","year":"2006","unstructured":"Goerke, C., Koller, J. & Wolz, C. Ciprofloxacin and trimethoprim cause phage induction and virulence modulation in Staphylococcus aureus. Antimicrob. Agents Chemother. 50, 171\u2013177 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"key":"30556_CR48","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1128\/JB.188.7.2726-2729.2006","volume":"188","author":"E Maiques","year":"2006","unstructured":"Maiques, E. et al. \u03b2-lactam antibiotics induce the SOS response and horizontal transfer of virulence factors in Staphylococcus aureus. J. Bacteriol. 188, 2726\u20132729 (2006).","journal-title":"J. Bacteriol."},{"key":"30556_CR49","doi-asserted-by":"publisher","first-page":"e1005797","DOI":"10.1371\/journal.pgen.1005797","volume":"12","author":"EA Ronayne","year":"2016","unstructured":"Ronayne, E. A., Wan, Y. C. S., Boudreau, B. A., Landick, R. & Cox, M. M. P1 ref endonuclease: A molecular mechanism for phage-enhanced antibiotic lethality. PLoS Genet. 12, e1005797 (2016).","journal-title":"PLoS Genet."},{"key":"30556_CR50","doi-asserted-by":"crossref","unstructured":"Al-Anany AM, Fatima R, Nair G, Mayol JT, Hynes AP. 2024. Temperate phage-antibiotic synergy across antibiotic classes reveals new mechanism for preventing lysogeny. mBio 15.","DOI":"10.1128\/mbio.00504-24"},{"key":"30556_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro1085","author":"E Mahenthiralingam","year":"2005","unstructured":"Mahenthiralingam, E., Urban, T. A. & Goldberg, J. B. The multifarious, multireplicon Burkholderia cepacia complex. Nat. Rev. Microbiol. https:\/\/doi.org\/10.1038\/nrmicro1085 (2005).","journal-title":"Nat. Rev. Microbiol."},{"key":"30556_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmicb.2015.00305","volume":"6","author":"NL Podnecky","year":"2015","unstructured":"Podnecky, N. L., Rhodes, K. A. & Schweizer, H. P. Efflux pump-mediated drug resistance in burkholderia. Front. Microbiol. 6, 1\u201325 (2015).","journal-title":"Front. Microbiol."},{"key":"30556_CR53","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S1526-0542(02)00185-9","volume":"3","author":"DP Speert","year":"2002","unstructured":"Speert, D. P. Advances in Burkholderia cepacia complex. Pediatric. Respir. Rev. 3, 230\u2013235 (2002).","journal-title":"Pediatric. Respir. Rev."},{"key":"30556_CR54","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1093\/jac\/dkp253","volume":"64","author":"E Peeters","year":"2009","unstructured":"Peeters, E., Nelis, H. J. & Coenye, T. In vitro activity of ceftazidime, ciprofloxacin, meropenem, minocycline, tobramycin and trimethoprim\/sulfamethoxazole against planktonic and sessile Burkholderia cepacia complex bacteria. J. Antimicrob. Chemother. 64, 801\u2013809 (2009).","journal-title":"J. Antimicrob. Chemother."},{"key":"30556_CR55","doi-asserted-by":"publisher","first-page":"e0168615","DOI":"10.1371\/journal.pone.0168615","volume":"12","author":"WN Chaudhry","year":"2017","unstructured":"Chaudhry, W. N. et al. Synergy and order effects of antibiotics and phages in killing pseudomonas aeruginosa biofilms. PLoS ONE 12, e0168615 (2017).","journal-title":"PLoS ONE"},{"key":"30556_CR56","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.3389\/fmicb.2020.01358","volume":"11","author":"DL Peters","year":"2020","unstructured":"Peters, D. L., McCutcheon, J. G. & Dennis, J. J. Characterization of novel broad-host-range bacteriophage DLP3 Specific to stenotrophomonas maltophilia as a potential therapeutic agent. Front. Microbiol. 11, 1358 (2020).","journal-title":"Front. Microbiol."},{"key":"30556_CR57","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12864-019-5674-5","volume":"20","author":"DL Peters","year":"2019","unstructured":"Peters, D. L., McCutcheon, J. G., Stothard, P. & Dennis, J. J. Novel Stenotrophomonas maltophilia temperate phage DLP4 is capable of lysogenic conversion. BMC Genomics 20, 300 (2019).","journal-title":"BMC Genomics"},{"key":"30556_CR58","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1186\/1471-2164-11-599","volume":"11","author":"KH Lynch","year":"2010","unstructured":"Lynch, K. H., Stothard, P. & Dennis, J. J. Genomic analysis and relatedness of P2-like phages of the Burkholderia cepacia complex. BMC Genomics 11, 599 (2010).","journal-title":"BMC Genomics"},{"key":"30556_CR59","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1128\/AAC.00954-06","volume":"51","author":"J Zhou","year":"2007","unstructured":"Zhou, J. et al. Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis. Antimicrob. Agents Chemother. 51, 1085\u20131088 (2007).","journal-title":"Antimicrob. Agents Chemother."},{"key":"30556_CR60","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/aje\/153.4.345","volume":"153","author":"TG Liou","year":"2001","unstructured":"Liou, T. G. et al. Predictive 5-year survivorship model of cystic fibrosis. Am. J. Epidemiol. 153, 345\u2013352 (2001).","journal-title":"Am. J. Epidemiol."},{"key":"30556_CR61","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jmii.2014.03.001","volume":"49","author":"HJ He","year":"2016","unstructured":"He, H. J. et al. Erythromycin resistance features and biofilm formation affected by subinhibitory erythromycin in clinical isolates of Staphylococcus epidermidis. J. Microbiol. Immunol. Infect. 49, 33\u201340 (2016).","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"30556_CR62","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1111\/ajt.15503","volume":"19","author":"S Aslam","year":"2019","unstructured":"Aslam, S. et al. Early clinical experience of bacteriophage therapy in 3 lung transplant recipients. Am. J. Transplant. 19, 2631\u20132639 (2019).","journal-title":"Am. J. Transplant."},{"key":"30556_CR63","doi-asserted-by":"publisher","first-page":"e14041","DOI":"10.1111\/tid.14041","volume":"25","author":"G Haidar","year":"2023","unstructured":"Haidar, G. et al. Phage therapy in a lung transplant recipient with cystic fibrosis infected with multidrug-resistant Burkholderia multivorans. Transplant Infect. Dis. 25, e14041 (2023).","journal-title":"Transplant Infect. Dis."},{"key":"30556_CR64","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01621-25","author":"R Fatima","year":"2025","unstructured":"Fatima, R., Nair, G., Mayol, J., MacNeil, L. T. & Hynes, A. P. Temperate phages increase antibiotic effectiveness in a Caenorhabditis elegans infection model. MBio https:\/\/doi.org\/10.1128\/mbio.01621-25 (2025).","journal-title":"MBio"},{"key":"30556_CR65","doi-asserted-by":"publisher","first-page":"107927","DOI":"10.1016\/j.celrep.2020.107927","volume":"32","author":"BS Weber","year":"2020","unstructured":"Weber, B. S. et al. Genetic and chemical screening in human blood serum reveals unique antibacterial targets and compounds against klebsiella pneumoniae. Cell Rep. 32, 107927 (2020).","journal-title":"Cell Rep."},{"key":"30556_CR66","doi-asserted-by":"publisher","first-page":"e00196","DOI":"10.1128\/jb.00196-23","volume":"205","author":"MK Ruest","year":"2023","unstructured":"Ruest, M. K., Supina, B. S. I. & Dennis, J. J. Bacteriophage steering of Burkholderia cenocepacia toward reduced virulence and increased antibiotic sensitivity. J. Bacteriol. 205, e00196-e223 (2023).","journal-title":"J. Bacteriol."},{"key":"30556_CR67","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1128\/IAI.01249-07","volume":"76","author":"KD Seed","year":"2008","unstructured":"Seed, K. D. & Dennis, J. J. Development of Galleria mellonella as an alternative infection model for the Burkholderia cepacia complex. Infect. Immun. 76, 1267\u20131275 (2008).","journal-title":"Infect. Immun."},{"key":"30556_CR68","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1128\/JCM.38.2.910-913.2000","volume":"38","author":"E Mahenthiralingam","year":"2000","unstructured":"Mahenthiralingam, E. et al. Diagnostically and experimentally useful panel of strains from the burkholderia cepacia complex. J. Clin. Microbiol. 38, 910\u2013913 (2000).","journal-title":"J. Clin. Microbiol."},{"key":"30556_CR69","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.femsle.2005.06.050","volume":"250","author":"ST Cardona","year":"2005","unstructured":"Cardona, S. T., Wopperer, J., Eberl, L. & Valvano, M. A. Diverse pathogenicity of Burkholderia cepacia complex strains in the Caenorhabditis elegans host model. FEMS Microbiol. Lett. 250, 97\u2013104 (2005).","journal-title":"FEMS Microbiol. Lett."},{"key":"30556_CR70","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1128\/AEM.07097-11","volume":"78","author":"KH Lynch","year":"2012","unstructured":"Lynch, K. H., Stothard, P. & Dennis, J. J. Characterization of DC1, a broad-host-range Bcep22-like podovirus. Appl. Environ. Microbiol. 78, 889\u2013891 (2012).","journal-title":"Appl. Environ. Microbiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30556-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30556-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30556-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T01:01:32Z","timestamp":1768179692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30556-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["30556"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-30556-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"850"}}